Eisai Parades Pipeline Before Investors During First US R&D Day
This article was originally published in PharmAsia News
Management highlighted Eisai’s neurology and oncology assets during a Scientific Day in New York, the first formal R&D briefing the Japanese pharma’s US subsidiary has held in more than 20 years operating in the country.
You may also be interested in...
All clear from monitoring board means firms will roll into the Phase III portion of the AMARANTH trial.
H3 Biomedicine is using publicly available cancer genomics data to discover compounds that could treat small subsets of patients.
Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.